Changmeng Cai

14PUBLICATIONS

43CO-AUTHORS

Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer cell biologyCancer genetics

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (14)

Sort by Publication Date:

|Jun 23, 2026

Identification of targets of clinical FOXA1 mutants involved in EMT and immune suppression in prostate cancer.

|May 01, 2026

Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer.

|Mar 21, 2025

Heterogeneous Responses to High-Dose Testosterone in Castration-Resistant Prostate Cancer Tumors with Mixed Rb-Proficient and Rb-Deficient Cells.

Maryam Labaf, Wanting Han, Songqi Zhang

|Oct 28, 2024

Voluntary Exercise Attenuates Tumor Growth in a Preclinical Model of Castration-Resistant Prostate Cancer.

Nicolas Berger, Benjamin Kugler, Dong Han

|Jun 08, 2024

FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer.

Zifeng Wang, Scott L Townley, Songqi Zhang

|Sep 04, 2023

Demethylation of EHMT1/GLP Protein Reprograms Its Transcriptional Activity and Promotes Prostate Cancer Progression.

Anna Besschetnova, Wanting Han, Mingyu Liu

Pageof 3

Frequent Collaborators

Shuai Gao

Wanting Han

Jill A Macoska

Housheng Hansen He

Dong Han

Muqing Li

Steven P Balk

Zifeng Wang

Susan Patalano

Mingyu Liu

Frequent Collaborators

Shuai Gao

Wanting Han

Jill A Macoska

Housheng Hansen He